TITLE

Widespread tenofovir gel use has substantial impact in South Africa

PUB. DATE
June 2011
SOURCE
PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research analysis in 2011 that claims widespread use of tenofovir gel in South Africa could prevent more than two million new HIV infections and save one million lives over 20 years. The research was conducted by the World Health Organization (WHO), the Centre for the AIDS Program of Research in South Africa (CAPRISA) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). The CAPRISA 004 trial reportedly showed that the vaginal microbicide significantly reduces HIV transmission from men to women.
ACCESSION #
62656913

 

Related Articles

  • World Health Organization reforms forthcoming. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, pE647 

    Information about the 64th World Health Assembly in Geneva, Switzerland. It states that the assembly discussed the importance to reform World Health Organization (WHO) operations, the new strategy to fight HIV and the approval of a comprehensive influenza preparedness plan. It notes that the...

  • Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the... Mayans, Marti Vall; Robertson, Susan E. // Bulletin of the World Health Organization;2000, Vol. 78 Issue 9, p1166 

    Reports on the use of the World Health Organization (WHO) Vaccine Trial Registry to assess whether and how investigators are monitoring adverse events following immunization (AEFI) in vaccine trials. Objective of the WHO Immunization Safety Priority; AEFI according to reports; Points for...

  • WHO Clinical trial registry platform: addition of China and India.  // Weekly Epidemiological Record;8/17/2007, Vol. 82 Issue 33, p303 

    The article reports on the expansion of the clinical trial registry platform of the World Health Organization (WHO), which is set to include trial registers from China and India. The move is a major step for policymakers and scientists because it will enable them to track local research...

  • Statement on publishing clinical trials in Indian biomedical journals. Satyanarayana, K.; Sharma, A.; Parikh, P.; Vijayan, V. K.; Sahu, D. K.; Nayak, B. K.; Gulati, R. K.; Parikh, M. N.; Singh, P. P.; Bavdekar, S. B.; Sreehari, U.; Sahni, P. // Indian Journal of Cancer;Apr-Jun2008, Vol. 45 Issue 2, p39 

    The article focuses on the launching of Clinical Trial Registry India in New Delhi on July 20, 2007. The launching of the online registry was hosted by the National Institute of Medical Statistics (NIMS) and the Indian Council of Medical Research (ICMR). The online registry was established to...

  • Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the... Mayans, Marti Vall; Robertson, Susan E. // Bulletin of the World Health Organization;2000, Vol. 78 Issue 9, p1166 

    Reports on the use of the World Health Organization (WHO) Vaccine Trial Registry to assess whether and how investigators are monitoring adverse events following immunization (AEFI) in vaccine trials. Objective of the WHO Immunization Safety Priority; AEFI according to reports; Points for...

  • WHO calls for full disclosure of clinical trials. Woolston, Chris // Nature;4/23/2015, Vol. 520 Issue 7548, p411 

    The article reports that the World Health Organization (WHO) has called for full disclosure of clinical-trial results in biomedical research.

  • Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/23/2011, Vol. 343 Issue 7816, p177 

    No abstract available.

  • Is Trial Registration Still an Issue? Hindin, Toby Jane // Applied Clinical Trials;Jul2006, Vol. 15 Issue 7, p12 

    The author reflects on the new standards for the registration of all human medical research announced by the World Health Organization (WHO). The International Clinical Trials Registry Platform will act as a conduit for standardization of all registries. WHO hopes to create transparency on all...

  • The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. Piaggio, Gilda; Elbourne, Diana; Schulz, Kenneth F.; Villar, José; Pinol, Alain P. Y.; Gülmezoglu, A. Metin // BMC Medical Research Methodology;2003, Vol. 3, p19 

    Background: The aim of this article is to explore ways in which selection bias and ascertainment bias can be reduced and investigated in trials, by using the example of a drug trial carried out in both developed and developing countries in hospital delivery wards. Methods: We describe an...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics